BD to Invest $110M to Expand Production of Prefillable Syringes

BD, a global medical technology company, is investing $110 million to expand its production of prefillable syringes, helping accelerate biologic and GLP-1 drug delivery and supporting pharmaceutical reshoring in the U.S.

This investment will bring BD Neopak Glass Prefillable Syringe production to Columbus, Nebraska, creating approximately 120 new jobs and reinforcing the company’s supply resilience within its Pharmaceutical Systems portfolio. Supply is expected to begin in mid-2026.

The investment will also support additional line upgrades and capacity improvements across the site, ensuring BD can meet growing global demand for advanced injectable solutions. Furthermore, BD will enhance cannula manufacturing capabilities at the site.

“As demand for biologics and GLP-1s accelerates, BD is strengthening its American manufacturing footprint to support U.S.-based drug delivery innovation and supply chain resiliency,” said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. “This investment in Nebraska, advances our long-term growth strategy and reflects our commitment to partnering with biopharmaceutical innovators as they bring advanced therapies to patients who require next-generation drug delivery solutions.”

This announcement builds on BD’s recent investment of more than $35 million to expand prefilled flush syringe manufacturing in Columbus. These investments are part of BD’s commitment to invest more than $2.5 billion in U.S. manufacturing capabilities over the next five years.

Other global pharmaceutical companies committed to investing in U.S. manufacturing capabilities include AstraZeneca, Sanofi, Johnson & Johnson and Novartis.